Navigation Links
LCA-Vision's Medical Advisory Board Voices Support for Current Management
Date:3/18/2009

CINCINNATI, March 18 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV), a leading provider of laser vision correction services under the LasikPlus(R) brand, announces that its 11-member Medical Advisory Board has expressed unanimous support for LCA-Vision management's actions to address concerns raised by the Company's surgeons in June 2008. The full text of the Medical Advisory Board's letter to LCA-Vision Chairman E. Anthony Woods appears below:

    March 16, 2009

    Dear Mr. Woods:

    The Medical Advisory Board unanimously recognizes and unanimously
    supports the efforts taken by current management to address the
    issues raised by us this past June.  We brought our concerns to your
    attention to help restore LasikPlus to its rightful industry
    leadership position.  The actions taken by management since our
    meetings have addressed many of our concerns and are, in our
    opinion, strong steps in the right direction.  These actions
    include, but are not limited to: more surgeon involvement with
    management, significant strategic planning and changes involving
    marketing and operations, and more openness and transparency at all
    levels.

    We greatly appreciate what the management team has done over the
    past 8 months. We strongly support the initiatives that are evolving
    and the growing collaborative efforts to make LasikPlus a stronger
    enterprise. We anticipate these actions are the foundation of a true
    partnership and look forward to working with management to achieve
    what is best for our patients and the Company.  Together we can use
    these difficult economic times to strengthen the LasikPlus position;
    together we can ensure a bright future.

    Respectfully,
    The Medical Advisory Board of LCA Vision, Inc. 

Steven Straus, LCA-Vision chief executive officer, said, "The Company is benefiting from our strengthened partnership with our Medical Advisory Board and surgeons across our LasikPlus(R) vision centers. The surgeons' input is extremely valuable in helping us navigate through a challenging environment that has significantly impacted our business and our industry. We look forward to building further upon this foundation as we work together toward a prosperous future."

Due to the nature of the Consent process, your voting instruction is extremely important and time sensitive. LCA-Vision urges all stockholders to vote their GOLD cards to REVOKE CONSENT on all three proposals. Please discard any proxy card that you receive from the Joffe Group. If you have already voted to consent and wish to change your vote, you have every right to revoke your consent and vote the GOLD proxy. Only the latest dated card counts.

LCA-Vision filed its Definitive Consent Revocation Statement ("Consent Revocation Statement") with the Securities and Exchange Commission on Monday, February 9, 2009, and copies of the Consent Revocation Statement with a GOLD Consent Revocation Card were mailed to stockholders beginning February 10, 2009. The Consent Revocation Statement can be obtained immediately from the SEC's website at the following link:

http://idea.sec.gov/Archives/edgar/data/1003130/000114420409006021/v139094_defc14a.htm

or from the Investor Relations section of the Company's website at www.lasikplus.com and www.lca-vision.com. Copies of the Consent Revocation Statement and consent revocation card may also be obtained from Georgeson Inc.

Additional Information:

Georgeson Inc. has been retained by LCA-Vision as consent revocation solicitation agent. Stockholders with questions are encouraged to call Georgeson toll-free 1-800-457-0109. Copies of the Company's Consent Revocation Statement, and any other documents filed by LCA-Vision with the SEC in connection with the consent solicitation can be obtained free of charge from the SEC's website at www.sec.gov, from the Company's website at www.lasikplus.com and www.lca-vision.com, or from Georgeson.

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 75 LasikPlus(R) fixed-site laser vision correction centers in 32 states and 57 markets in the United States and a joint venture in Canada. Additional company information is available at www.lca-vision.com and www.lasikplus.com.

               Earning Trust Every Moment.
                                    Transforming Lives Every Day.

    For Additional Information

    Company Contact:                  Investor Relations Contact:
    Barb Kise                         Jody Cain
    LCA-Vision Inc.                   Lippert/Heilshorn & Associates
    513-792-9292                      310-691-7100


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now ... country. The AutismOne 2016 Conference, which is being held May 25-29 at the Loews ... elsewhere about helpful interventions and causes of chronic illness in children. , Very recent ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - ... Medical Devices sector report, "Aesthetic Devices - Medical Devices ... currently in pipeline stage. This report ... and primary research by GlobalData,s team of industry experts. ... removed or altered based on the availability and relevance ...
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016  Neurocrine ... the Company will report its fourth quarter and year-end ...  February 11, 2016.  Neurocrine will then host a live ... and provide a Company update Thursday afternoon, February 11, ... Time). http://www.neurocrine.com . --> http://www.neurocrine.com ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016   GS1 ... healthcare professionals to guide them through GS1 Standards implementation ... Drug Administration (FDA) Unique Device Identification (UDI) rule. ... GS1 US; Beth Gibson , senior director industry ... , industry development director, GS1 US --> ...
Breaking Medicine Technology: